尼达尼布治疗亚洲进展性纤维化性间质性肺疾病:INBUILD试验亚组结果
BACKGROUND AND OBJECTIVE: In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity (FVC) with an adverse event profile characterized mainly by gastrointestinal events.…
要点
- 尼达尼布减缓亚洲进展性纤维化性ILD患者FVC下降,52周差异91.0 ml/年
- UIP样纤维化模式亚组同样获益,FVC差异94.1 ml/年
- 不良事件导致停药率尼达尼布组19.0%、安慰剂组13.8%
核心结论
- 在亚洲进展性纤维化性ILD患者中,尼达尼布减缓FVC下降速率,不良事件多数可控。
主要发现
- 不良事件导致治疗停药:尼达尼布组19.0%,安慰剂组13.8%。
临床怎么用
- 对亚洲进展性纤维化性ILD患者,可考虑尼达尼布以减缓FVC下降,需关注不良事件及停药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity (FVC) with an adverse event profile characterized mainly by gastrointestinal events. We analysed the effects of nintedanib in the subset of Asian subjects. METHODS: Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis who had shown progression of ILD at any time within the prior 24 months despite management deemed appropriate in clinical practice were randomized to receive nintedanib or placebo. We analysed the rate of decline in FVC (ml/year) over 52 weeks in all Asian subjects and in Asian subjects with a usual interstitial pneumonia (UIP)-like fibrotic pattern on high-resolution computed tomography (HRCT). RESULTS: One hundred sixty-four subjects in the INBUILD trial were of Asian race. The rate of decline in FVC (ml/year) over 52 weeks in this subgroup was -116.8 in the nintedanib group and -207.9 in the placebo group (difference: 91.0 [95% CI: 8.1, 173.9]; nominal p = 0.03). In Asian subjects with a UIP-like fibrotic pattern on HRCT, the rate of decline in FVC (ml/year) over 52 weeks was -130.1 in the nintedanib group and -224.2 in the placebo group (difference: 94.1 [5.5, 182.7]; nominal p = 0.04). Adverse events led to treatment discontinuation in 19.0% of the nintedanib group and 13.8% of the placebo group. CONCLUSION: In Asian patients with progressive fibrosing ILDs, nintedanib reduced the rate of decline in FVC with adverse events that were manageable for most patients.
引用
- Inoue Y, Wells AU, Song JW, et al. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial. Respirology. 2023. PMID: 36642509. doi:10.1111/resp.14452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。